Pegylation of IFNα, where polyethylene glycol (PEG) molecules are bound to the native protein, has been shown to reduce in vitro activity but increase the stability and plasma half-life of IFNα [3], and have therefore largely replaced conventional IFNα in CHC treatment [4]. The gene discussed is IFNA2; the disease is cryohydrocytosis.